Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Blood Rev. 2021 Mar 16;49:100825. doi: 10.1016/j.blre.2021.100825

Table 4.

Recommended clinical criteria to consider a trial of treatment free remission in patients with chronic phase CML (45,48).

Criteria for discontinuation of TKI therapy
Age ≥ 18 years
History of good compliance
TKI therapy for ≥ 3 years
Quantifiable BCR-ABL1 transcript
Deep molecular response for ≥ 2 years
Chronic phase CML with no prior accelerated or blast phase CML
Access to reliable quantitative PCR testing
Monthly testing for months 1–6, bimonthly for month 7–12, and every three months afterwards
Prompt resumption of TKI therapy upon loss of major molecular response